Marché mondial des spiromètres – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché des spiromètres

Le marché des spiromètres continue de progresser grâce à des innovations dans les appareils portables, intégrant une connectivité sans fil pour la surveillance à distance. Les dernières méthodes incluent des analyses basées sur l'IA pour une évaluation précise de la fonction pulmonaire. Des technologies telles que les capteurs de débit à ultrasons améliorent la précision et l'expérience utilisateur. La croissance est tirée par l'augmentation de la prévalence des maladies respiratoires et de la demande de solutions de soins de santé à domicile, ce qui façonne des perspectives de marché solides.                                

Français La taille du marché mondial des spiromètres a été évaluée à 789,04 millions USD en 2023 et devrait atteindre 1 805,31 millions USD d'ici 2031, avec un TCAC de 10,9 % au cours de la période de prévision 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

A spirometer is a medical device used to measure lung function and capacity. It works by recording the volume of air inhaled and exhaled by the lungs during breathing exercises. Spirometry tests are crucial in diagnosing respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and monitoring lung health in various clinical settings. This device aids in assessing lung function for accurate diagnosis and treatment planning.           

Spirometer Market Dynamics

Drivers

• Increasing Respiratory Diseases

The rising prevalence of respiratory diseases such as COPD and asthma globally has significantly increased the demand for spirometry devices. These conditions require accurate diagnosis and ongoing monitoring of lung function, which spirometers provide. For instance, in 2023, the global spirometer market saw a notable surge in sales, driven by healthcare facilities' urgent need to manage and treat respiratory illnesses effectively through early detection and precise diagnostic tools such as spirometry.

• Integration with Electronic Health Records (EHRs)

Integration of spirometry devices with Electronic Health Records (EHRs) automates data capture, analysis, and storage, reducing manual entry errors and enhancing healthcare provider efficiency. For instance, seamless integration allows clinicians to access patients' historical spirometry data instantly during consultations, facilitating quicker and more informed treatment decisions. This integration not only improves patient care but also drives market expansion by demonstrating tangible benefits in terms of operational efficiency and patient outcomes.

Opportunities

• Rising Demand for Telemedicine and Remote Monitoring

The rising demand for telemedicine and remote monitoring, accelerated by the COVID-19 pandemic, has created significant opportunities in the spirometer market. Home-based spirometry devices enable patients to monitor lung function remotely, enhancing access to healthcare and reducing the need for frequent clinic visits. This trend has spurred innovation among device manufacturers, leading to the development of user-friendly, portable spirometers that cater to the growing preference for telehealth solutions.

• Rising Patient-Centric Care Initiatives

Rising patient-centric care initiatives emphasize personalized treatment plans tailored to individual health needs. Spirometry, pivotal in monitoring chronic respiratory conditions such as COPD, aligns with this trend by enabling precise diagnosis and ongoing management at the patient's convenience. This shift expands market opportunities as healthcare providers increasingly integrate spirometry into comprehensive, patient-centered care strategies, ensuring better health outcomes through proactive monitoring and tailored interventions.

Restraints/Challenges

• Risk of Infection Transmission

The risk of infection transmission through spirometry, involving direct contact with patients' breath, poses significant operational challenges in healthcare settings. Stringent infection control measures are essential but add to the complexity and cost of using spirometers. This risk can deter adoption and increase reluctance among healthcare providers to use spirometry devices, potentially hindering market growth and adoption rates. 

• High Cost of Devices

The high cost of spirometers, particularly advanced models for clinical use, poses a significant barrier to adoption in smaller healthcare facilities and regions with constrained budgets. This financial restraint hinders market penetration and limits accessibility to essential respiratory diagnostic tools. As a result, healthcare providers in these settings may face challenges in acquiring necessary equipment to effectively diagnose and manage respiratory conditions. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2022, RxCap, Inc. partnered with ZEPHYRx to integrate ZEPHYRx's online spirometry platform with RxCap's remote surveillance system. This collaboration enables RxCap's corporate clients, including healthcare providers and insurers, to monitor the lung health of patients with severe respiratory diseases remotely
• In August 2022, AstraZeneca collaborated with Alveofit to deploy IoT-enabled portable spirometers in U.S. clinics. These handheld devices connect to the internet, enabling online patient tracking and tele-spirometry. Integrated with comprehensive care management systems, they enhance respiratory care accessibility and efficiency
• In April 2021, Vitalograph launched the next-generation Pneumotrac spirometer in the U.S. This device, paired with Spirotrac PC software, is designed for precise respiratory diagnosis in both adult and pediatric patients, enhancing diagnostic capabilities and clinical management in respiratory healthcare

Spirometer Market Scope

The market is segmented on the basis of type, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Software
• Devices
  • Table-Top Spirometer
  •  Hand-Held Spirometer
  •  PC Based Spirometer
• Consumables and Accessories

Technology

• Volume Measurement Spirometer
• Flow Measurement Spirometer
• Peak Flow Meter

 Mechanism

• Flow-Sensing Spirometer
• Peak Flow Meters

Disease

• Bronchitis
• Emphysema
• Chronic Obstructive Lung Disease
• Lung Cancer
• Others

 Disposable Components

• Filters
• Sensors
• Tubes

 Application

• Asthma
• COPD
• Cystic Fibrosis
• Pulmonary Fibrosis
• Others

 End-User

• Hospitals
• Clinics
• Homecare

 Distribution Channel

• Over the Counter
• Direct Tender

Spirometer Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, type, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is projected to dominate the spirometer market due to the high prevalence of chronic obstructive pulmonary disease (COPD). This region's advanced healthcare infrastructure, coupled with robust research and development activities, contributes to the significant adoption of spirometry devices for the diagnosis and management of respiratory conditions.

Asia-Pacific is expected to witness significant growth in the spirometer market during the forecast period. This growth is driven by improving primary care initiatives aimed at early diagnosis and management of chronic lung diseases such as asthma and COPD, fostering increased adoption of spirometry technologies across the region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Croissance des infrastructures de santé Base installée et pénétration des nouvelles technologies

Le marché vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les biens d'équipement, la base installée de différents types de produits pour le marché, l'impact de la technologie à l'aide de courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché. Les données sont disponibles pour la période historique 2016-2021.

Analyse du paysage concurrentiel et des parts de marché des spiromètres

Le paysage concurrentiel du marché fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Certains des principaux acteurs opérant sur le marché sont :

• F. Hoffmann-La Roche, SA (Suisse)
• Mylan NV (États-Unis)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GSK plc. (Royaume-Uni)
• Novartis SA (Suisse)
• Bayer AG (Allemagne)
• Merck & Co., Inc. (États-Unis)
• AstraZeneca (Royaume-Uni)
• Cipla (États-Unis)
• Merck KGaA (Allemagne)
• LEO Pharma A/S (Danemark)
•  Sun Pharmaceutical Industries Ltd. (Inde)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• Fresenius Kabi AG (Allemagne)
•  Amneal Pharmaceuticals LLC. (États-Unis)

SKU-1373